Evaluation of H. pylori - Eradication Triple Therapy in Iraqi Peptic Ulcer Patients according to ABO Phenotypes: a New Study

Rana Hussein Kutaif1,  Manal Khalid Abdulridha2Ù­, Yassir Mustafa Kamal3, Akram Ajeel Najeeb4

 1Wasit Health Directorate, Ministry of Health , Wasit-10001, Iraq

2Ù­Departmentof Clinical Pharmacy/College of Pharmacy/Al-Mustansiriya University, Baghdad-10001, Iraq

3Department of Pharmacology and Toxicology/College of Pharmacy/ Al-Mustansiriya University, Baghdad-10001, Iraq

4Consultant gastroenterologist, Baghdad Teaching Hospital,Medical city, Baghdad-10001, Iraq

Received: 06-Jun-2017 , Accepted: 16-Jul-2017

Keywords: Peptic ulcer disease, ABO blood group phenotype, H. pylori, eradication therapy

http://dx.doi.org/10.20510/ukjpb/5/i4/155960

 

Full-Text PDF      

XML                    

Google Scholar  

How To Cite       

Abstract

Infection with H. pylori is an up growing  public health problem that affects approximately 50% of people in industrialized nations, and up to 80% in developing countries. Helicobacter pylori (H. pylori) infection had been identified as the main causes of peptic ulcer disease (PUD). Blood group A phenotype was associated with gastric ulcer (GU) and gastric carcinoma, while blood group O phenotype found to be associated with duodenal ulcer DU predominantly; however, no explanation for this association was received. This study was conducted to, first, determine the relationship between ABO blood groups and H. pylori infection in peptic ulcer patients, and second, to study the response to the two weeks H. pylori eradication triple therapy in peptic ulcer patients carrying different blood groups. A total of  84 patients who presented  with symptoms of PUD and showed positive endoscopic examination of PUD and evidence of H. pylori infectionby histology and stool antigen test, were divided into four groups according to ABO blood group phenotype. All H. pylori infected patients received standard H. pylori eradication triple therapy for 14 days duration. Patients were followed up by re- endoscopic examination after 2 months of treatment course. The percentage of H. pylori infection in patients with peptic ulcer disease carrying blood group O was higher than other blood group phenotype. In H. pylori-infected peptic ulcer patients, higher incidence of gastric ulcer (GU) was noticed among blood group A carriers, while higher incidence of duodenal ulcer (DU) was found among blood group O carriers when compare with other blood group phenotypes.  Fourteen days triple therapy showed lower eradication rate in H. pylori infected blood group O peptic ulcer patients, while a higher response to the standard H. pylori eradication triple therapy was found among patients with blood group B phenotype.

1 Introduction

Infection with H. pylori is a substantial public health problem that affects 20-50% of people in developed nations, and up to 80% in less developed countries1, H. pylori infection is one of the widespread chronic bacterial infections in the world2. Most infected people by H. pylori remain asymptomatic and only minorities develop PUD3. It seems to be dependent on genetic factors of the host and virulence factors presented by this microorganism that determine the clinical significance of the infection 4. It has been shown for many years, that blood group A had been associated with gastric carcinoma, while blood group O have been associated with DU; however, no explanation for this association was received5. Previously, it was found that infection by this gram-negative bacillus was associated with ABO blood groups in Brazilian patients performed upper gastrointestinal endoscopy6.
In early 90s, Borén et al. reported that H. pylori bacterium chooses to attach itself to the Lewis b antigen (Leb), which is rich in fucose and is expressed on the surface of the epithelial cells of the gastric mucosa 7. Also Alkout et al. demonstrated that H antigen represent an important receptor expressed in the gasteroduodenal mucosa to which H. pylori adhere8. Blood group apecific antigens (ABH-blood group) are complex fucosylated carbohydrates expressed on the surface of erythrocytes of all individuals of blood group A, B, or O, respectively. The ABH antigens are also found in other tissues such as gastric mucosal cells and their secretions, saliva, milk, and tear fluid 9. Secretor status is the secretion of blood group antigens ABO (H) in fluids. In ABH secretors, people secrete antigens according to their blood groups (for example, group O people will secrete H antigen, group A people will secrete A and H antigens, etc)10. People who are ABH secretor probably have an ability to produce some biological decoys or metabolic chaff out into the gastric secretions that is very specific for H. pylori colonization. Also, in ABH non-secretors the immune response against H. pylori appears to be lower and H. pylori appears to attach with higher aggressiveness and cause more inflammation11.
In chronic H. pylori infection, could be implicated in the induction of auto reactive antibodies in the pathogenesis of H. pylori- associated atrophic gastritis12.The frequencies of different Lewis-secretor phenotypes vary markedly among different ethnic populations. It is well established that about 80% of the world’s population are ABH antigens secretors, and only 20% are non secretors but with some racial differences13.One of the studies in Kurds region (Kurdistan-Iraq) showed that 78% of ABH are secretors and 22% of them are non secretors14.
Both ABH and Lewis antigens on the gastric and duodenal mucosa are synthesized through a specific enzyme (glycosyl transferase), which incorporates molecules of fucose in type I oligosaccharide precursor15. H antigen that is present on the cells of individuals with O blood group is the base for A and B antigens, but A and B antigens differ only in their added terminal sugars, which are controlled by specific enzymes called transferase enzymes13,16. The biologic significance of the A/B transferase has not been clearly demonstrated, but it would be expected that loss of this functional protein in group O patients would have some deleterious consequences for patients of this blood type17. The Lewis blood group antigen system composed of type 1 antigens, Lea and Leb and type 2 antigens, Lex and Ley, both biochemically related to the ABO blood group phenotypes, additionally, Lewis blood typing can identify both the Le antigen phenotype and secretor status of most people18. The Leb is the predominant ABO blood group antigen expressed on epithelial cell surfaces and red cells of secretors, whereas Lea is expressed by non secretors, although some secretors have been found to express Lea in variable amounts on their epithelial cells8. Surface and foveolar epithelia (columnar epithelia) coexpress either Lea and Lex in Le(a+,b−) individuals or Leb and Ley in Le(a−,b+) individuals, whereas a glandular epithelium lacks type 1 antigens (Lea and Leb) and expresses Lex and Ley irrespective of the secretor phenotype19. The O and Le (a-b+) phenotypes express a greater quantity of these fucosylated antigens in comparison with other groups and this difference predisposed these carriers to H. pylori infection20. H. pylori have several lipopolysaccharides such as O antigen on its outer membrane expressing Lea and Leb antigens.

The Lewis antigen expression on the membrane of H. pylori for antigenic mimicry may create persistent colonization and surviving of bacteria in the stomach mucosa21. H. pylori bind to H and Leb antigens (secretors) in the gastric mucosa22,23.
Triple therapy has been the accepted standard of care for H. pylori eradication since the mid-1990s24. However, it may not be the most effective first-line treatment in certain regions, due to increasing antimicrobial resistance. There is controversy over the most effective duration of treatment for this regimen25. Evidence suggests that therapy is more successful if extended to >7 days26,27, and many experts now recommend 10-14 days treatment28. The initial effectiveness of this regimen revealed that around 80–90% has progressively declined below 70–80%, in the last few years29. Resistance rates of Helicobacter pylori to antibiotics vary in different countries, and even in different regions of the same country. Choice of treatment can be modified according to antibiotic-resistance rates of H. pylori. The ideal target of therapeutic regimen for H. pylori infection should achieve an eradication rate of ≥ 80%30.
In some countries, triple therapy with a proton-pump inhibitor, amoxicillin and clarithromycin is still the best option. In countries with clarithromycin resistance of more than 20%, bismuth-containing quadruple therapy, or non-bismuth sequential or concomitant therapies may be preferred option31. Studies conducted in Iraq demonstrated higher prevalence H. pylori positive than H. pylori negative among population and dyspeptic patients approximately (74-77%)32.33.
Previous studies which showed that DUs were associated with blood group O, while GUs and gastric carcinoma were associated with blood group A34,35. Strong association was found among Iraqi patients as well36 this study is another attempt in this respect (though at a smaller scale), it may be (at least to our best knowledge); the first attempt to compare patients response to triple therapy in different blood groups or ABO phenotypes.

2 Materials and Methods

2.1 Study design

This is a prospective case control study performed on newly diagnosed patients with PUD (male and female), who attended the Endoscopy Unit from April 2013 to August 2014. Patients were registered in the study after signing a written consent, and the study was agreed by the Ethical Committee. Patients were enrolled if they showed positive endoscopic examination of PUD. Data were collected through the direct interview with the patient. Prior to endoscopy, questionnaire was prepared to take the history of the disease, and the characteristic of each patient including age, gender, blood group, the duration of complaint, smoking, alcohol intake, NSAIDs usage, presence of family history, signs, symptoms and previous treatment as well as the reason for requesting endoscopic assessment.

2.2 Patients

2.2.1 Inclusion criteria

• Patients aged between (15-77) years old.
• Patients with peptic ulcer disease (DU or GU) achieved by endoscopy.
• Patients positive for H. pylori by two methods: the histological examination and stool antigen test or UBT performed in the specialized gastroenterology laboratory.

2.2.2 Exclusion criteria

• Patients with drug history over the past month which mimic those used in the present study.
• Patients who had received proton pump inhibitors, H2-blockers for a minimum of 2 weeks before test according to pervious study37.
• Patients who had received bismuth compounds in the past 4 weeks.
• Patients who had severe concurrent disease that might affect the medical evaluation of this study.
• Pregnant and lactating Women.
• Patients who had severe gastroesophageal reflux disease (GERD), gastric tumors or history of gastrectomy.
• Patients with PUD who were smoker, NSAID users or alcoholics.
• Patients allergic to the study medications.

According to these criteria 116 patients whom presented with symptoms of PUD and showed positive endoscopic examination of PUD, 28 patients were H. pylori negative confirmed by two methods (histological examination and stool antigen test), and 88 patients present with H. pylori positive were included in the study, but 84 patients receive H. pylori eradication therapy continued throughout the study period, they were allocated into four groups:

• Blood group A; included 24 patients
• Blood group B; included 16 patients
• Blood group AB; included 12 patients
• Blood group O; included 32 patients

All H. pylori infected patients received H. pylori eradication triple therapy (clarithromycin (500 mg) capsules, amoxicillin (1g) capsules and esomeprazole (20mg) capsules) given twice daily for 14 days.
Patients were followed up by re-endoscopic examination after 2 months at end of treatment. Successful H. pylori eradication was represented as a negative Stool antigen test or UBT,and improved clinical symptoms. H. pylori considered positive if two tests (histological investigation plus stool antigen test or UBT) were positive. Three biopsies were taken from the antral part of the stomach of each patient for histopathological examination during the endoscopic investigation because H. pylori were not evenly distributed throughout the gastric mucosa38.
Venous blood samples were taken from each patient after endoscopy for checking blood group at the beginning of the study (baseline samples). ABO phenotypes and Rh factor evaluations were carried out by standard hem agglutination assays39. H. pylori antigen in human fecal specimens, according to the technique of H. pylori antigen rapid test device (feces)40. Breath examination provides a rapid, non-invasive process of identifying the presence of active H. pylori infection and is frequently used to check whether eradication of the bacteria has been successful41.

2.3 Statistical analysis

Data were analyzed using SAS 2012 (Statistical Analysis System) Version 9.1. Chi-square test was used to compare between parameters among different patients groups42. Analysis of H. pylori eradication efficacy was assessed via “per-protocol”analysis basis. Values with P3.

3 Results and Discussions

3.1 Demographic data and disease characteristics:

Several studies demonstrated higher prevalence of H. pylori positive than H. pylori negative in peptic ulcer and dyspeptic patients43,44,45. Furthermore, the probability of H. pylori positive individuals to have any lesion in the gastric mucosa was found to be 10 folds greater than H. pylori negative individuals. Studies conducted in Iraq demonstrated higher prevalence H. pylori positive than H. pylori negative among population and dyspeptic patients approximately (74-77)%. Also similar finding was found in peptic ulcer patients enrolled in this study; where 75% of them showed positive H. pylori infection. Also previous studies presented variations of H. pylori infection among blood donors in different regions in the same place and in different countries46. Basic characteristics of the PUD patients involved in this study are shown in table 1.
The mean age of the studied patients, was 39.11 years, which was similar that reported a mean age of about 39.2 years47. On the contrary, other studies found a mean age of (46-50 years)48,49,50.The percentages for H. pylori positive patients among males and females were 64.29% and 35.71%, respectively; these finding was compatible with other studies where male gender showed only a marginal predominance51,52. This may be due to a significant higher infection rates in men than women and the literatures regarding the relationship between gender and H. pylori infection is conflicting. It is possible that women are more likely to have infection eradicated with antimicrobials used for other illnesses53. Other studies found that males, and females are infected at the same rate54,55. Additionally, the percentage of H. pylori positive among patients with GUs and DUs was higher than in H. pylori negative patients. This is consistent with other studies that reported a higher H. pylori infection incidence in both GUs and DUs.56. The distribution of ABO phenotypes in H. pylori positive PUD patients in this study was as follow: 28.57% for blood group A, 38.1% for blood group O, 19.04% for blood group B and 14.29% for blood group AB. This may be comparable with other studies that reported a higher incidence of H. pylori infection within blood group O of PUD patients20,57. Besides, Rh positivity in H. pylori positive patients was 96.43%, this finding was consistent with the study by Jaff et al. (2011), who reported that Rh positivity was 92.5% in H. pylori positive patients. A similar study also found that Rh positivity were 92.9% in H. pylori positive patients5. The main presenting symptom of PUD patients in the present study was epigastric pain (73.81%), heart burn (71.43% of patients) and vomiting (46.43%). Epigastric pain was the major complaint reported by several studies49,58,59.

3.2 Distribution of H. pylori positive and negative in patients with peptic ulcer disease according to ABO phenotypes

The percentages of ABO phenotypes were analyzed in this study separately in accordance with H. pylori infection and non-infection (table 2). We observed that there was an association between H. pylori negative and blood group A, these finding was similar to that previously reported a higher prevalence of blood group A among the uninfected patients. Also the current study revealed a strong association of blood group O with H. Pylori infection, which was consistent with a recent study in Swedish population done by Ryberg et al. who found positive associations between the presence of blood group O, and H. pylori infection in PUD60. Furthermore, these results may be reinforced by data obtained from other researchers showing a greater susceptibility of blood group O patients to H. pylori infection20,57,61,62.

The association of H. Pylori with blood group antigens fascinated doctors for few decades when an association was discovered between the infection of H. Pylori and blood group O62. In the early 1990s, Boren et al. demonstrated that Leb antigen, which is found mostly in blood group O, functions as a receptor for H. pylori adhesions, mediating bacterial adherence to the gastric mucosal surface, which is essential for bacterial colonization. This evidence was further supported by Alkout et al. who demonstrated that H-antigen, expressed on the gastroduodenal cells, acted as a receptor for H. Pylori. This fucosylated antigen (H antigen) is not modified to A or B antigens in blood group O, which points to the fact that there is a positive correlation between blood group O and the infections caused by H. Pylori. Furthermore, substitution of the Leb antigen with blood group A and B determinants results in failure of H. pylori binding7. Reduced exposure of the Leb antigen in blood groups A and B carriers could result in lower H. pylori infection rates, and a predominantly in persons with blood group O63.A recent study in Iraq by Jaff et al. found that individuals with blood group O have significantly higher incidence of Le (a-b+) (secretor status) than in non-O blood group individuals.

Individuals with the Le (a–b+) phenotype (secretors) secrete Lea as well as Leb and ABH substances in body fluids. Thus, it is possible that the Leb present in other body secretions such as gastric mucus may bind to specific glycoproteins of H. pylori, and hinder the binding of H. pylori to the gastric mucosa. The increased susceptibility of blood group O persons to peptic ulcer might be partly due to blood group O individuals express a higher inflammatory responses to H. pylori with higher levels of lymphocyte infiltration in the gastrointestinal mucosa64, a lower level of Von Willebrand’s factor65, higher density of colonized H. pylori66, and a higher frequency of secretor status. All these together, may explain these individuals’ increased susceptibility to peptic ulceration. However, Bhuiyan et al. showed that blood group A is found to be related with H. Pylori infection67. Earlier study demonstrated that H. Pylori infection is related to both O and A blood group type, and a negative relation with AB group23. On the contrary, only few studies have demonstrated that blood group O do not represent a risk factor for H. pylori infection55,68.
Recent findings about H. pylori strains from different populations have revealed that H. pylori strains differed by approximately 1500-fold with respect to binding affinities, and there was considerable diversity related to the Bab A gene sequences69,70. There is heterogeneity in the expression of outer membrane proteins, especially Bab A, among different H. pylori strains, and there is heterogeneity in the capacity of H. pylori to bind to the (Leb) antigen on the surface of gastric epithelial cells. This heterogeneity may be a factor that explains some of the differences in the clinical outcomes of this infection69. Not all strains are equally specific for O and (Leb) antigen; many strains from outside South America can bind to A and (Leb) antigen in addition to O and Leb. For example, Peruvian strains are related to Spanish strains but not to Asian strains70. A study by Con et al. (2010) revealed higher frequency of babA2 in Japan (96.8%) than in Costa Rica (73.7%). In comparison, the frequency of babA2/B was higher in Costa Rica (11.6%) than in Japan (1.1%), the study also suggested that frequencies of babA2 and babA2/B exhibit geographic differences71. Another virulence factor characterized recently in H. pylori is sialic acid–binding adhesion (Sab A). The frequency of Sab A also exhibits geographic differences and is more common in European than Japanese72,73. This diversity in H. pylori strains may explain different findings due to different geographic areas.

3.3 Distribution of gastric and duodenal ulcers according to ABO phenotypes

A higher incidence of GU (58.33%) in H. pylori positive was in blood group A when compared with other blood groups, while a higher incidence of DU (81.25%) in H. pylori positive was in blood group O when compared with other blood groups (Table 3).
These findings agree with previous studies, which showed that DUs were associated with blood group O, while GUs and gastric carcinoma were associated with blood group A74,75,76. Furthermore, Syeda et al mentioned that the incidence of DU was 1.38 times in people belonging to blood group O as compared to other blood groups77. This may be explained that DU were associated with acid hypersecrtion, predominantly in patients with blood group O, while GU in the body of the stomach occurring in patients with normal duodenum,were characterized by acid hyposecretion and this marked in patients with blood group A, the cause that blood type A is most likely to have gastric cancer78. Also Serum-pepsinogen level was found to be greater for individuals with blood group O than the blood group A. It is believed that the quantity of serum pepsinogen mass is in relation to the size of gastric secretory-cell. It is hypothesized that blood group culminates at the development of secretory cell mass, reinforcing that gastric peptic cell mass is larger in group O77. This might be reasons why blood group O is more susceptible to DU. While the association of blood group A with GU and carcinoma, which is also related with H. pylori infection. Many, other studies showed higher frequency of DU among patients with blood group O with significantly higher H. pylori positivity compared to other blood groups5,36, including Iraqi population.

3.4 Ulcer-healing efficacy of H. pylori eradication triple therapy in peptic ulcer disease patients according to ABO phenotypes

Per-protocol analysis was performed to compare eradication efficacy for all patients with different blood groups who finished the course of treatment. The healing efficacy of triple therapy regimens in of peptic ulcer disease in ABO phenotypes as follows: (58.33%) for blood group A, (50%) for blood group O, (75%) for blood group B and (66.67%) for blood group AB, table 4. The total efficacy which was obtained in general in respect to the regimens was (59.52%). Statistically highly significant difference (P<0.01) was found among ABO phenotypes according to stool antigen or UBT after 8 weeks. Patients with blood group O showed less healing efficacy than patients with blood group A, B and AB. On the other hand, patients carrying blood group B had a higher healing efficacy than those with other groups phenotypes.
Individuals with blood group O were found to be more susceptible to peptic ulcer disease for decades without known cause until the relationship between Lewis b antigens and the attachment of H. pylori to gastric mucosa was observed. As mentioned previously, the gastric mucosa of blood group O person are more prone for the attachment of H. pylori, because they had more receptors and Leb antigens mediated the attachment of H. pylori to the mucosa 23.Taking together all these evidence may provide a possible explanation to the low response of group O patients to H. pylori eradication triple therapy.


3.5 Ulcer-healing efficacy of H. pylori eradication triple therapy in peptic ulcer disease patients according to location of ulcer in different ABO phenotype

The present study showed that patients with blood group O has the least statistically significant (P<0.01) ulcer healing efficacy in DU and GU compared with other blood groups after 2 months of H. pylori eradication triple regimen, table 5. No matched studies to our best knowledge that could interpret our result. However, since patients with blood group O show higher density of colonization by H. pylori compared to other blood groups where epithelial cells bound significantly to H. pylori8. Previous studies, have demonstrated significant association between cagA-positive H. pylori strain, and the development of peptic ulcers among patients belonging to the blood group O6,79.

Previous study demonstrated that bacterial load in patients with cag A positive was greater than in patients with cag A negative both in the antrum and corpus (p < 0.01)80. So patients with blood group O show higher density of colonization by H. pylori8. Furthermore, high antral density of H. pylori was associated with a significant reduction in the eradication rate after anti-H. Pylori treatment81. Also patients with blood group O have high gastric acidity as previously mentioned77,78, and high gastric acidity was associated with reduced antibiotic therapy efficacy82, or potentially has antibiotic resistance compared with other blood groups83.

4 Conclusion

Association between H. pylori infection, ABO blood groups and Rh status in PUD has been widely evaluated over the past. This study is another attempt in this respect (though at a smaller scale), it may be to the best knowledge the first attempt to compare patients response to H. pylori eradication triple therapy in different blood groups or ABO phenotypes, which showed lower eradication rate after H. pylori eradication coarse in infected peptic ulcer patients carrying blood group O phenotype compared to those holding other blood groups, with higher percentage of H. pylori-infection, and higher incidence of duodenal ulcer (DU). Further study is warranted to assess the response to other H. pylori eradication protocols in patients carrying blood group O phenotype in an attempt to improve the response rate.

5 Acknowledgments

The author would like to thank Al-Mustansiriyah University (www.uomustansiriyah.edu.iq) Baghdad - Iraq for its support in the present work and special thanks to Baghdad Teaching Hospital,Medical city for their help in providing the practical platform of this study. [This work was presented as a poster in the (`7th International Conference on Drug Discovery and Therapy`, held from 15th February - 18th February, 2016, in UAE), though not yet published].

6 Conflict of interest

The author declared none

7 Author`s contributions

Manal Khalid Abdulridha( the corresponding author) brings the study design into it,s applicable state along with drafting the manuscript. And the litreture review, result discussion, lab work, and data collection was carried out by Akram Ajeel Najeeb and Rana Hussein Kutaif. Finally Yassir Mustafa Kamal arranged the data into tabular form. All authers read and approved the final manuscript.

8 References

1. Konturek PC, Konturek SJ, Celinski K. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J Pineal Res. 2010; 48: 318-323.
2. Khalifa MM, Sharaf RR,Aziz RK. Helicobacter pylori: a poor man’s gut pathogen? Gut Pathogens. 2010; 2: 2-12.
3. Salih BA. Helicobacter pylori infection in developing countries: the burden for how long? Saudi J Gastroenterol. 2009; 15(3): 201–207.
4. Tadesse E, Daka D, Yemane D. Seroprevalence of Helicobacter pylori infection and its related risk factors in symptomatic patients in southern Ethiopia. BMC Research Notes 2014; 7:834.
5. Bayan K, Tuzun Y, Yilmaz S. Clarifying the relationship between ABO/Rhesus blood group antigens and uppergastrointestinal bleeding. Dig Dis Sci. 2009; 54: 1029-1034.
6. Mattos DE, Cintra JR, Brandão de Mattos CC. ABO blood groups and Helicobacter pylori cagA infection: evidence of an association. J Venom Toxins ins Trop Dis. 2010; 17(1): 87-95.
7. Borén T, Falk P, Roth KA. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 1993; 262: 1892- 1895.
8. Alkout AM, Blackwell CC, Weir DM. Isolation of a cell surface comonent of Helicobacter pylori that binds H type 2, Lewis a and Lewis b antigens. Gastroenterology. 1997; 112:1179–1187.
9. Linden S, Mahdavi J, Semino-Mora C. Role of ABO secretor status in mucosal innate immunity and H. pylori infection. PLOS Pathog. 2008; 4(1): 90-98
10. D`adamo PJ and Kelly GS. Metabolic and immunologic consequences of ABH secretor status. Alternative Medicine Review. 2001; 6(4): 390- 405.
11. Rad R, Gerhard M, Lang R. The Helicobacter pylori blood group antigen binding adhesion facilitates bacterial colonization and augments a nonspecific immune response. J Immunol. 2002; 168: 3033-3041.
12. Lozniewski A, Haristoy X, Rasko D. Influence of Lewis antigen expression by H. pylori on bacterial internalization by gastric epithelial cells. Immun. 2003; 71: 2902-2906.
13. Jaff MS. Higher frequency of secretor phenotype in O blood group – its benefits in prevention and/or treatment of some diseases. Int J Nanomedicine. 2010; 5:901–905.
14. Jaff MS, Bilbas FAH. Frequency of the ABH blood group antigen secretors among kurds. Zanco J Med Sci. 2007; 11(2):15–19.
15. Mattos LC, Cintra JR, Sanches FE. ABO, Lewis, secretor and non-secretor phenotypes in patients infected or uninfected by the Helicobacter pylori bacillus.Sao Paulo Med J/Rev Paul Med. 2002; 120(2): 55-8.
16. Shibata A, Hamajima N, Ikehara Y. ABO blood type, Lewis and Secretor genotypes, and chronic atrophic gastritis: a cross- sectional study in Japan .Gastric Cancer. 2003; 6: 8–16.
17. Anstee DJ. The relationship between blood groups and disease. Blood. 2010; 115(23): 4635–4643.
18. Heneghanma, Mccarthy CF and Moran AP. Relationship of Blood Group Determinants on Helicobacter pylori Lipopolysaccharide with Host Lewis Phenotype and Inflammatory Response. Infection and Immunity. 2000; 68(2): 937–941.
19. Rasko DV, Keelan M, Wilson TJ M. Lewis antigen expression by Helicobacter pylori. J Infect Dis. 2001; 184: 315-321.
20. Jaff MS. Relation between ABO blood groups and Helicobacter pylori infection in symptomatic patients. Clin Exp Gastroenterol. 2011; 4: 221-6.
21. Rothenbacher D, Weyermann M, Bode G. Role of Lewis A and Lewis B blood group antigens in Helicobacter pylori infection. Helicobacter. 2004; 9(4): 324–329.
22. Backstrom A, Lundberg C, Kersulyte D. Metastability of Helicobacter pylori bab adhesin genes and dynamics in Lewis b antigen binding. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(48):16923–16928.
23. Kanbay M, Gür G, Arslan H. The relationship of ABO blood group, age, gender, smoking, and Helicobacter pylori infection. Dig Dis Sci. 2005; 50: 1214- 7.
24. Malfertheiner P, Megraud F, O’Morain C. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56(6):772–81.
25. Egan BJ, Katicic M, O’Connor H. Treatment of Helicobacter pylori infection. Helicobacter. 2007; 12 (1):31-37.
26. Pandit V, Suresh S and Hemanth Joshi H. Peptic ulcer and its mangment. Journal of Pharmacy Research. 2008; 1( 2): 245-252.
27. Fuccio L, Minardi ME, Zagari RM. Meta-analysis: duration of first-line proton pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 147(8):553-62.
28. Malfertheiner P, Megraud F, O`Morain CA. Managment of helicobacter pylori infection-the Maastrict IV/Florence consensus Report. Gut. 2012; 61(5): 646-664.
29. O’Connor A, Gisbert J, McNamara D. Treatment of Helicobacter pylori infection. Helicobacter. 2010; 15(1):46-52.
30. Alahdab YO and Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol. 2014; 20(18): 5302-5307.
31. Tepes B, O`Connor A, Gisbert JP. Treatment of Helicobacter pylori infection. Helicobacter. 2012; 17(1): 36-42.
32. Hussein NR, Robinson K and Atherton JC. A study of age-specific Helicobacter pylori seropositivity rates in Iraq. Helicobacter.2008; 13(4): 306-7.
33. Al-Windi A, Hussain AH and Salih N. Seroprevalence of anti- Helicobacter pylori antibodies in population of Sulaimani governorate/Kurdistan Region/Iraq. Journal of Zankoy Sulaimani.- Part A 2013; 15(3): 175-185.
34. Garratty G. Blood groups and disease: a historical perspective. Transfus Med Rev. 2000; 14(4): 291–301.
35. Edgren G, Hjalgrim H, Rostgaard K. Risk of Gastric Cancer and Peptic Ulcers in Relation to ABO Blood Type: A Cohort Study. American Journal of Epidemiology. 2010; 172: 1280–1285.
36. Abdulridha MK. The Relationship between ABO Blood Group Distribution and the incidence of Upper Gastric and Duodenal Ulcer in Iraqi Patients. Iraqi J Pharm Sci. 2013; 22(1):97-103.
37. Hunt RH, Xiao SD, Megraud F. Helicobacter pylori in developing countries. J Gastrointestin Liver Dis. 2011; 20(3): 299-304.
38. Abo-Shadi MA, El-Shazly TA and Al-Johani MS. Clinical, Endoscopic,Pathological and Serological Findings of Helicobacter pylori Infection in Saudi Patients with Upper Gastrointestinal Diseases. British Journal of Medicine & Medical Research. 2013; 3(4): 1109-1124.
39. Jones, Scott ML and Voak D. Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients transfusion. Medicine. 1995; 5: 171-184.
40. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. New England J Med. 1990; 322: 90916.
41. Batista CA, Silva FM, Barbuti RC. Neither genotype nor the gastric colonization site of Helicobacter pylori are predictive factors for the development of erosive esophagitis in patients with peptic ulcer disease, 1 year after eradication. Arq Gastroenterol. 2009; 46 (3): 204-8.
42. Statistical Analysis System, User`s Guide. Statistical.Version 9.1th ed. SAS 2012. Inst. Inc. Cary. N.C. USA.
43. Tadege T, Mengistu Y, Desta k. Seroprevalence of Helicobacter pylori Infection in and its Relationship with ABO Blood Groups. Ethiop J Health Dev. 2005; 19(1):56-60.
44. Muller LB, Fagundes RB, Moraes CC. Prevalence of Helicobacter pylori infection and gastric cancer precursor lesions in patients with dyspepsia. Arq Gastroenterol. 2007; 44 (2):93-8.
45. Nwodo EN, Yakubu SE, Jatau ED. Seroprevalence of Helicobacter pylori Infection in Patients with Gastritis and Peptic Ulcer Disease in Kaduna, Kaduna State, Nigeria. African Journal of Basic & Applied Sciences. 2009; 1(5-6): 123-128.
46. Zhubi B, Baruti-Gafurri Z, Mekaj Y. Helicobacter pylori infection according to ABO blood group among blood donors in Kosovo. J Health Sci. 2011;1(2):83-89.
47. Hajiani E, Hashemi J and Vosoghi T. Comparison of a 10 day triple and a two-week quadruple therapy in eradicating Helicobacter pylori infection in patients referred to imam khomeini hospital clinics ahwaz, iran. Jundishapur journal of natural pharmaceutical products. 2008; 3(1): 45-52.
48. Batista CA, Silva FM, Barbuti RC. Neither genotype nor the gastric colonization site of Helicobacter pylori are predictive factors for the development of erosive esophagitis in patients with peptic ulcer disease, 1 year after eradication. Arq Gastroenterol. 2009; 46 (3): 204-8.
49. Javed M, Amin K, Muhammad D. Prevalence of H. Pylori. Professional Med. 2010; 17(3):431-439.
50. Kim YS, Kim SJ, Yoon JH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011; 34: 1098–1105.
51. Park HG, Jung MK, Jung JT. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naı¨ve patients, Aliment Pharmacol Ther. 2012; 35(1): 56–65.
52. Sasidharan S, Ghayethry B, Ravichandran M. Prevalence of Helicobacter pylori infection among patients referred for endoscopy: Gender and ethnic differences in Kedah, Malaysia. Asian Pacific Journal of Tropical Disease. 2012; 2: 55-59.
53. Naja F, Kreiger N and Sullivan T. Helicobacter pylori infection in Ontario: Prevalence and risk factors. Can J Gastroenterol. 2007; 21 (8): 501-506.
54. Nwodo EN, Yakubu SE, Jatau ED. Seroprevalence of Helicobacter pylori Infection in Patients with Gastritis and Peptic Ulcer Disease in Kaduna, Kaduna State, Nigeria. African Journal of Basic & Applied Sciences. 2009; 1(5-6): 123-128.
55. Petrović M, Artiko V, Novosel S. Relationship between Helicobacter pylori infection estimated by 14C-urea breath test and gender, blood groups and rhesus factor. Hell J Nucl Med. 2011; 14(1): 21-4.
56. Leite KRM, Darini E, Canavez FC. Helicobacter pylori and cagA gene detected by polymerase chain reaction in gastric biopsies: correlation with histological findings, proliferation and apoptosis. São Paulo Med J. 2005; 123(3):113-8.
57. Hassoon WA, Melconian AK and AL-Safar JM. Study the Relationship between Hemodialysis (HD) Patients and Their ABO Blood Grouping as Well as Screening of Hemodialysis Access-related Bacterial Infections. Journal of Biological Sciences. 2013; 5(6): 291.
58. Megraud F, Coenen S, Versporten A. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62: 34–42.
59. Yasir S, Moin F and Akhtar SM. Frequency of Helicobacter Pylori Infection on Histopathology in Patients with Dyspepsia. American Journal of Clinical Medicine Research. 2014; 2(3):53-56.
60. Ryberg A, Petersson F, Redeen S. Host Gene Polymorphisms in Relation to Helicobacter Pylori Infection and Associated Diseases in a Population Based Cohort. Gastroenterology Research. 2013; 6(6):207-218.
61. Martins LC, de Oliveira Corvelo TC, Oti HT. ABH and Lewis antigen distributions in blood, saliva and gastric mucosa and H pylori infection in gastric ulcer patients. World J Gastroenterol. 2006; 12(7): 1120-4.
62. Valliani A, Khan F, Ahmed B. Factors Associated with Helicobacter Pylori Infection, Results from a Developing Country- Pakistan. Asian Pac J Cancer Prev. 2013; 14(1):53-56.
63. Niv Y, Fraser G, Delpre G. Helicobacter pylori infection and blood groups. Am J Gastroenterol. 1996; 91:101-104.
64. Aspinal GO, Monteir MA, Shave RT, Kurjanczy LA, Penner JL. Lipopolysaccharides of Helicobacter pylori serogroups O:3 and O:6. Structures of a class of lipopolysaccharides with reference to the location of oligomeric units of D-glycero-α-D-manno-heptose residues. Eur. J. Biochem.1997;248:592–601.
65. Franchini M, Capra F, Targher G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J . 2007; 5:14.
66. Atherton JC, Tham KT, Peek RM. Density of Helicobacter pylori infection in vivo as assed by quantitative culture and histology. J Infect Dis. 1996; 174: 552-556.
67. Bhuiyan TR, Qadri F, Saha A. Infection by Helicobacter pylori in Bangladeshi children from birth to two years: relation to blood group, nutritional status, and seasonality. Pediatr Infect Dis J 2009; 28: 79-85.
68. Keramati MR, Sadeghian MH, Ayatollahi H. Role of the Lewis and ABO Blood Group Antigens in Helicobacter pylori Infection. Malays J Med Sci.2012; 19(3): 17-21.
69. Hennig EE, Mernaugh R, Edl J. Heterogeneity among Helicobacter pylori strains in expression of the outer membrane protein BabA. Infect Immun. 2004; 72(6):3429–3435.
70. Aspholm-Hurtig M, Dailide G, Lahmann M. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science. 2004; 305(5683): 519–522.
71. Con SA, Takeuchi H, Nishioka M. Clinical relevance of Helicobacter pylori babA2 and babA2/B in Costa Rica and Japan. World J Gastroenterol. 2010; 16(4): 474–478.
72. Molnar B, Galamb O, Sipos F. Molecular pathogenesis of Helicobacter pylori infection: The role of bacterial virulence factors. Dig Dis. 2010; 28(4-5): 604–608.
73. Shao L, Takeda H, Fukui T. Genetic diversity of the Helicobacter pylori sialic acid-binding adhesin (sabA) gene. Biosci Trends. 2010; 4(5): 249–253.
74. Smith AW, Aathithan S, Power EG. Blood group antigens and Helicobacter pylori infections. Lancet. 1994; 343: 543.
75. Garratty G. Blood groups and disease: a historical perspective.Transfus Med Rev 2000; 14(4): 291–301.
76. Edgren G, Hjalgrim H, Rostgaard K. Risk of Gastric Cancer and Peptic Ulcers in Relation to ABO Blood Type: A Cohort Study. American Journal of Epidemiology. 2010; 172: 1280–1285.
77. Najeeb ST and Mushtaq A. Relationship between blood groups and ulcers: Revisiting the pioneer work. 2012; 62:1367.
78. Dkeet AC. Gastric ulceration and Pyloric Sphincteric cylinder; the pyloric Sphincteric cylinder in Health and disease, Ch29, (4th ed.), 1998; p138.
79. Jafarzadeh A, Ahmedi-Kahanali J, Bahrami M. Seroprevalence of anti-Helicobacter pylori and anti-CagA antibodies among healthy children according to age, sex, ABO blood groups and Rh status in south-east of Iran. Turk J Gastroenterol. 2007; 18(3):165- 71.
80. Belda S, Saez J, Santiba´n˜ez M. Relationship between bacterial load, morbidity and cagA gene in patients infected by Helicobacter pylori. Clinical Microbiology and Infection. 2012; 18:E251–E253
81. Lai YC, Wang TH, Huang SH. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol. 2003; 9(7): 1537-1540.
82. Megraud F. Helicobacter pylori and antibiotic resistance. Gut. 2007; 56 (11): 1502.
83. Lee JY, Kim N, Kim MS. Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance. Dig Dis Sci. 2014; 59(6): 1235-43.